IRWD

1.36

5.56% -0.08

Handel nachbörslich: 1.41 0.05 +3.68%

Ironwood Pharmaceuticals Inc (IRWD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.44

Offen:

$1.35

24-Stunden-Volumen:

1.47M

Relative Volume:

0.50

Marktkapitalisierung:

$586.50M

Einnahmen:

$400.57M

Nettoeinkommen (Verlust:

$9.21M

KGV:

34.00

EPS:

0.04

Netto-Cashflow:

$146.36M

1W Leistung:

-6.85%

1M Leistung:

-10.53%

6M Leistung:

-67.85%

1J Leistung:

-83.23%

1-Tages-Spanne:

$1.345

$1.44

1-Wochen-Bereich:

$1.32

$1.505

52-Wochen-Spanne:

$1.32

$8.45

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Firmenname

Ironwood Pharmaceuticals Inc

Sektor

Healthcare (1178)

Branche

Drug Manufacturers - Specialty & Generic (1)

Telefon

617-621-7722

Adresse

100 SUMMER STREET, SUITE 2300, BOSTON, MA

Mitarbeiter

Twitter

@ironwoodpharma

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

IRWD's Discussions on Twitter

Vergleichen Sie IRWD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IRWD Ironwood Pharmaceuticals Inc	1.36	586.50M	400.57M	9.21M	146.36M	0.04
ZTS Zoetis Inc	159.61	71.47B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.19	47.98B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.45	47.20B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	14.85	17.02B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	307.36	13.80B	2.76B	1.11B	898.10M	22.77

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-09-09	Eingeleitet	Leerink Partners	Market Perform
2024-08-08	Herabstufung	CapitalOne	Overweight → Equal Weight
2024-01-17	Eingeleitet	Craig Hallum	Buy
2023-12-14	Eingeleitet	Wells Fargo	Overweight
2023-11-09	Eingeleitet	Jefferies	Buy
2023-09-28	Eingeleitet	JMP Securities	Mkt Outperform
2022-09-02	Eingeleitet	CapitalOne	Overweight
2022-04-22	Eingeleitet	Piper Sandler	Overweight
2020-09-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-06-17	Eingeleitet	Northland Capital	Outperform
2019-07-10	Fortgesetzt	Credit Suisse	Neutral
2019-03-27	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-02-25	Hochstufung	H.C. Wainwright	Sell → Neutral
2019-01-24	Hochstufung	JP Morgan	Underweight → Neutral
2018-11-07	Herabstufung	Credit Suisse	Outperform → Neutral
2018-11-07	Herabstufung	JP Morgan	Neutral → Underweight
2018-07-23	Eingeleitet	H.C. Wainwright	Sell
2018-05-09	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-01-05	Herabstufung	BofA/Merrill	Buy → Underperform
2017-12-06	Herabstufung	Mizuho	Buy → Neutral
2017-07-21	Herabstufung	JP Morgan	Overweight → Neutral
2017-05-03	Eingeleitet	Wells Fargo	Outperform
2017-04-07	Bestätigt	Mizuho	Buy
2017-02-22	Bestätigt	Barclays	Equal Weight
2016-11-04	Bestätigt	Mizuho	Buy
2016-10-24	Bestätigt	Wedbush	Neutral
2016-10-10	Bestätigt	Mizuho	Buy
2016-09-27	Bestätigt	WallachBeth	Hold

Alle ansehen

Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten

Mar 31, 2025

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire

Mar 27, 2025

Mar 25, 2025

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 25, 2025

Mar 23, 2025

Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World

Mar 23, 2025

Mar 21, 2025

StockNews.com Downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Hold - Armenian Reporter

Mar 21, 2025

Irritable Bowel Syndrome Treatment Market Future Business - openPR.com

Mar 21, 2025

Mar 20, 2025

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Blank Check On Growth? - Stocks Register

Mar 20, 2025

Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $8.60 - Defense World

Mar 20, 2025

Mar 10, 2025